Seikagaku Corp. | Income Statement

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Sales/Revenue
29,614
29,522
30,962
29,589
30,175
28,384
Cost of Goods Sold (COGS) incl. D&A
11,223
12,130
12,871
13,247
13,008
13,114
Gross Income
18,391
17,392
18,091
16,342
17,167
15,270
SG&A Expense
11,613
15,009
15,947
15,059
15,745
14,292
EBIT
4,937
2,383
2,144
1,283
1,422
978
Unusual Expense
551
-
29
-
-
25
Non Operating Income/Expense
1,461
1,554
1,344
1,166
3,869
1,819
Interest Expense
21
17
36
31
27
22
Pretax Income
5,949
4,008
3,500
2,477
5,327
2,859
Income Tax
1,204
358
922
689
1,404
614
Consolidated Net Income
4,745
3,650
2,578
1,787
3,922
2,244
Net Income
4,745
3,650
2,578
1,787
3,922
2,244
Net Income After Extraordinaries
4,745
3,650
2,578
1,787
3,922
2,244
Net Income Available to Common
4,745
3,650
2,578
1,787
3,922
2,244
EPS (Basic)
83.53
64.25
45.38
31.54
69.29
39.75
Basic Shares Outstanding
57
57
57
57
57
56
EPS (Diluted)
83.53
64.25
45.38
31.54
69.29
39.75
Diluted Shares Outstanding
57
57
57
57
57
56
EBITDA
6,713
4,995
5,338
4,205
4,350
3,880
Other Operating Expense
1,841
-
-
-
-
-
Non-Operating Interest Income
123
88
77
59
62
109

About Seikagaku

View Profile
Address
Marunouchi Center Building, 10/F
Tokyo Tokyo 100
Japan
Employees -
Website http://www.seikagaku.co.jp
Updated 07/08/2019
Seikagaku Corp. engages in the manufacture and sale of pharmaceuticals and medical devices specifically related to glycoconjugates. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection.